2014 Psychopharmacology Update Institute
Treating the Refractory Patient: Adding Expertise to Evidence-based Methods
January 10-11, 2014
Laurence L. Greenhill, M.D. and Jean A. Frazier, M.D., Co-Chairs
Sheraton New York Hotel and Towers—New York, NY
Program Schedule and More Details Coming Soon!
Institute Goals and Overview
In the past year, the media has been busy documenting the risks of psychopharmacological treatments for children and adolescence, such as diversion of stimulant medications, overuse of second generation antipsychotics in foster children, abuse of prescription medications, and metabolic syndrome developing in preschoolers treated with psychiatric medications. At the same time, questions have arisen about the practice of continuation of psychopharmacological treatments in non-responsive children and adolescents who have been refractory to all types of interventions by child and adolescent psychiatrists. This Institute reviews and updates participants about the possible medical and non-medical factors that lead to lack of treatment response and methods to detect and manage such factors.
Questions posed include:
- What are the non-medical factors that interfere with a pediatric patient’s response to psychiatric medications?
- Are there important differences among diagnoses associated with refractoriness to medication interventions and how can they be managed?
- What are the barriers for pediatric patients and their families that mitigate against full participation in psychiatric medication treatment?
- What do the latest data say about the balance of benefit to risk in using psychotropic medication, including second generation antipsychotics and stimulants, in symptomatic and non-symptomatic children with diagnoses of autism spectrum disorders, bipolar disorder, or children at risk for schizophrenia?
- What are factors that occur in real-word clinic settings compared to randomized clinical trials that decrease the response of children and adolescents to psychiatric medications?
- How can the office practitioner reduce the risk of diversion of psychotropic medications when treating college age youth and young adults with stimulants?
- What are the latest evidence-based data on new interventions, medical or non-medical, for ADHD, autism, and Tourette’s Disorder?
At the conclusion of this CME activity, the participant will be able to:
- List a group of non-medical reasons when their child and adolescent psychiatry patients do not respond to medication treatments.
- Give examples of cases involving child and adolescent patients with ADHD, depression, Tourette’s Disorder, bipolar, or early onset psychosis and identify the factors associated with their failure to respond to psychiatric medications.
- Describe the barriers to full participation in medication treatment that are associated with non-response or refractory symptoms.
- Discuss the differences between the response of research subjects in randomized clinical trials and office practice that lead to poor response to psychiatric medications.
- Discuss the differential risk for the different preparations of the same psychiatric medication to diversion and misuse (e.g. the immediate release preparations versus the long duration preparations), and which are less problematic in youth of college or transitional age.